OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Complex biotherapeutics present unique analytical challenges for developers.
FDA Approves Additional J&J Vaccine Batch; AstraZeneca Launches Variant Trial
Public-private consortium is tasked with advancing domestic pharmaceutical production.
New biotherapeutics both drive and benefit from innovative development technologies.
Meeting Development and Manufacturing Demands for Emerging Therapies
July 30, 2021
Emergent BioSolutions is being allowed to restart manufacturing operations for the J&J COVID-19 vaccine at its Bayview, Baltimore, Md., facility.
Entries are now open for the 18th Annual CPhI Pharma Awards in Milan.
VICO Therapeutics’ drug candidate, VO659, for treating Huntington’s Disease was granted orphan drug designation by FDA.
In the first half of 2021, the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research approved 29 novel therapies.
July 29, 2021
Thermo Fisher Scientific has added a new suite of immune repertoire assays that offers high detection rates of malignant clones, allowing researchers to better assess blood cancers.
Kineret (anakinra) is under evaluation by EMA's CHMP as a treatment for adult COVID-19 patients who are at an increased risk of severe respiratory failure.
EMA's CHMP has taken the decision to start a rolling review of Vidprevtyn—Sanofi Pasteur’s COVID-19 vaccine.
ERS Genomics and Japan SLC have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Byondis and Glycotope have formed an agreement to discover and develop antibodies that target specific glyco-epitopes.
Summa Equity has acquired a majority stake in science tools business Axion BioSystems with the intent of further entering the CGT market.